Characteristics and survival of patients with advanced cancer and p53 mutations

Oncotarget

Volumn 5, Issue 11, 2014, Pages 3871-3879

  Said, Rabih ^a,b   Ye, Yang ^a   Hong, David S ^a   Janku, Filip ^a   Fu, Siqing ^a   Naing, Aung ^a   Wheler, Jennifer J ^a   Kurzrock, Razelle ^a,c   Thomas, Christoforos ^d   Palmer, Gary A ^e   Hess, Kenneth R ^a   Aldape, Kenneth ^a   Tsimberidou, Apostolia M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d University of Houston   (United States)

^e FOUNDATION MEDICINE   (United States)

Author keywords

Matched therapy; Molecular aberrations; P53 mutations

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ADULT; ADVANCED CANCER; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CARCINOGENESIS; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; GENE FUNCTION; GENE IDENTIFICATION; GENE LOCATION; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; OVERALL SURVIVAL; PATIENT ASSESSMENT; PROTEIN DETERMINATION; PROTEIN FUNCTION; SURVIVAL RATE; TISSUE CHARACTERIZATION; TUMOR SUPPRESSOR GENE; WILD TYPE; GENETICS; MUTATION; NEOPLASMS; PHASE 1 CLINICAL TRIAL (TOPIC); PROGNOSIS; SURVIVAL; TREATMENT OUTCOME;

CLINICAL TRIALS, PHASE I AS TOPIC; FEMALE; GENES, P53; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASMS; PROGNOSIS; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84903545565     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2004     Document Type: Article

References (33)

1. Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP. Awakening guardian angels: drugging the p53 pathway. Nature reviews Cancer. 2009;9:862-73.
2. Girardini JE, Napoli M, Piazza S, Rustighi A, Marotta C, Radaelli E, et al. A Pin1/mutant p53 axis promotes aggressiveness in breast cancer. Cancer Cell. 2011;20:79-91.
3. Muller PA, Caswell PT, Doyle B, Iwanicki MP, Tan EH, Karim S, et al. Mutant p53 drives invasion by promoting integrin recycling. Cell. 2009;139:1327-41.
4. Adorno M, Cordenonsi M, Montagner M, Dupont S, Wong C, Hann B, et al. A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell. 2009;137:87-98.
5. Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM, et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell. 2004;119:861-72.
6. Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT, et al. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell. 2004;119:847-60.
7. Muller PA, Trinidad AG, Timpson P, Morton JP, Zanivan S, van den Berghe PV, et al. Mutant p53 enhances MET trafficking and signalling to drive cell scattering and invasion. Oncogene. 2013;32:1252-65.
8. Liu K, Ling S, Lin WC. TopBP1 mediates mutant p53 gain of function through NF-Y and p63/p73. Mol Cell Biol. 2011;31:4464-81.
9. Irwin MS, Kondo K, Marin MC, Cheng LS, Hahn WC, Kaelin WG, Jr. Chemosensitivity linked to p73 function. Cancer Cell. 2003;3:403-10.
10. Moll UM, Erster S, Zaika A. p53, p63 and p73-solos, alliances and feuds among family members. Biochim Biophys Acta. 2001;1552:47-59.
11. Caulin C, Nguyen T, Lang GA, Goepfert TM, Brinkley BR, Cai WW, et al. An inducible mouse model for skin cancer reveals distinct roles for gain-and loss-of-function p53 mutations. The Journal of clinical investigation. 2007;117:1893-901.
12. Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, Hruban RH, et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell. 2005;7:469-83.
13. Robles AI, Harris CC. Clinical outcomes and correlates of TP53 mutations and cancer. Cold Spring Harbor perspectives in biology. 2010;2:a001016.
14. Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P, Olivier M. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene. 2007;26:2157-65.
15. Said R, Hong DS, Warneke CL, Lee JJ, Wheler JJ, Janku F, et al. P53 Mutations in Advanced Cancers: Clinical Characteristics, Outcomes, and Correlation between Progression-Free Survival and Bevacizumab-Containing Therapy. Oncotarget. 2013;4:705-14.
16. http://p53.free.fr/index.html.
17. Servomaa K, Kiuru A, Kosma VM, Hirvikoski P, Rytomaa T. p53 and K-ras gene mutations in carcinoma of the rectum among Finnish women. Molecular pathology: MP. 2000;53:24-30.
18. Lai H, Lin L, Nadji M, Lai S, Trapido E, Meng L. Mutations in the p53 tumor suppressor gene and early onset breast cancer. Cancer biology & therapy. 2002;1:31-6.
19. Muller PA, Vousden KH, Norman JC. p53 and its mutants in tumor cell migration and invasion. The Journal of cell biology. 2011;192:209-18.
20. Liu G, McDonnell TJ, Montes de Oca Luna R, Kapoor M, Mims B, El-Naggar AK, et al. High metastatic potential in mice inheriting a targeted p53 missense mutation. Proceedings of the National Academy of Sciences of the United States of America. 2000;97:4174-9.
21. Tullo A, D'Erchia AM, Honda K, Mitry RR, Kelly MD, Habib NA, et al. Characterization of p53 mutations in colorectal liver metastases and correlation with clinical parameters. Clinical cancer research: an official journal of the American Association for Cancer Research. 1999;5:3523-8.
22. Agapova LS, Ilyinskaya GV, Turovets NA, Ivanov AV, Chumakov PM, Kopnin BP. Chromosome changes caused by alterations of p53 expression. Mutation research. 1996;354:129-38.
23. Tsimberidou AM, Iskander NG, Hong DS, Wheler JJ, Falchook GS, Fu S, et al. Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clinical cancer research: an official journal of the American Association for Cancer Research. 2012;18:6373-83.
24. Blagosklonny MV. Sequential activation and inactivation of G2 checkpoints for selective killing of p53-deficient cells by microtubule-active drugs. Oncogene. 2002;21:6249-54.
25. Sur S, Pagliarini R, Bunz F, Rago C, Diaz LA, Jr., Kinzler KW, et al. A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. Proceedings of the National Academy of Sciences of the United States of America. 2009;106:3964-9.
26. Apontes P, Leontieva OV, Demidenko ZN, Li F, Blagosklonny MV. Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell culture. Oncotarget. 2011;2:222-33.
27. Rao B, Lain S, Thompson AM. p53-Based cyclotherapy: exploiting the 'guardian of the genome' to protect normal cells from cytotoxic therapy. British journal of cancer. 2013;109:2954-8.
28. van Leeuwen IM, Rao B, Sachweh MC, Lain S. An evaluation of small-molecule p53 activators as chemoprotectants ameliorating adverse effects of anticancer drugs in normal cells. Cell cycle. 2012;11:1851-61.
29. Rao B, van Leeuwen IM, Higgins M, Campbel J, Thompson AM, Lane DP, et al. Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy. Oncotarget. 2010;1:639-50.
30. van Leeuwen IM. Cyclotherapy: opening a therapeutic window in cancer treatment. Oncotarget. 2012;3:596-600.
31. Herzog A, Bian Y, Vander Broek R, Hall B, Coupar J, Cheng H, et al. PI3K/mTOR Inhibitor PF-04691502 Antitumor Activity Is Enhanced with Induction of Wild-Type TP53 in Human Xenograft and Murine Knockout Models of Head and Neck Cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2013;19:3808-19.
32. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-16.
33. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-47.